Porter James Richard, President and CEO of an undisclosed company, has demonstrated a pronounced selling bias in his recent insider transactions, exclusively divesting shares of Nuvation Bio Inc. (NUVL) since August 2025. Over the past seven months, Richard executed 20 sales totaling approximately $14.48 million, with no offsetting purchases. The transactions were clustered in multi-million-dollar blocks, including a $1.59 million sale on March 6, 2026, followed by a $1.34 million disposition the same day. Earlier in January 2026, he liquidated four separate positions worth $798,080, $457,810, $383,420, and $353,405, reinforcing a consistent pattern of unwinding his NUVL stake.
The sales frequently coincided with market transactions (coded "M") and awards (coded "A"), suggesting routine disposition of vested equity. Notably, Richard's largest disposals occurred in October and September 2025, including a $1.27 million sale on September 15 and a $1.26 million transaction on October 16. The absence of any buy activity—his last recorded purchase predates the provided data—indicates a sustained reduction in exposure to NUVL. While the filings don't specify whether these sales represent full divestment, the scale and frequency suggest a deliberate effort to monetize holdings rather than periodic rebalancing. The transactions were executed at varying price points, with no single dominant valuation cluster evident in the reported amounts.
AI-assisted summary